Identifying patients at risk of late recovery (≥8 days) from acute exacerbation of chronic bronchitis and COPD  by Anzueto, Antonio et al.
Respiratory Medicine (2012) 106, 1258e1267Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedIdentifying patients at risk of late recovery (‡8 days)
from acute exacerbation of chronic bronchitis and
COPDAntonio Anzueto a,*, Marc Miravitlles b, Santiago Ewig c, Delfino Legnani d,
Stephanie Heldner e, Kathrin Stauch faUniversity of Texas Health Science Center and the South Texas Veterans Health Care System at San Antonio, USA
b Institut d’Investigacions Biome`diques August Pi i Sunyer (IDIBAPS), Ciber de Enfermedades Respiratorias (CIBERES),
Hospital Clinic, Barcelona, Spain
cThoraxzentrum Ruhrgebiet, Kliniken fu¨r Pneumologie und Infektiologie, EVK Herne und Augusta-Kranken-Anstalt Bochum,
Germany
dOspedale Luigi Sacco, Via G B Grassi 74, 20157 Milano, Italy
eBayer HealthCare, Building P300, 2nd Floor, A241, 13342 Berlin, Germany
fBayer HealthCare Germany GmbH, Building K 56, 51368 Leverkusen, Germany
Received 24 November 2011; accepted 1 June 2012
Available online 30 June 2012KEYWORDS
Exacerbation;
AECOPD;
AECB;
Moxifloxacin;
Observational;
Non-interventional* Corresponding author. University o
Blvd, San Antonio, Texas 78229, USA.
E-mail address: anzueto@uthscsa.
0954-6111/$ - see front matter ª 201
http://dx.doi.org/10.1016/j.rmed.20Summary
Objectives: To identify factors associated with late recovery (8 days from exacerbation start)
in patients with acute exacerbations of chronic bronchitis/COPD (AECB/AECOPD).
Methods: An international, observational, non-interventional study in outpatients with AECB/
AECOPD who received treatment for their exacerbation with the antibiotic moxifloxacin.
Factors analyzed for late recovery included patient demographic characteristics, geographic
region and disease severity. Additionally, logistic regression analysis was undertaken to iden-
tify factors associated with late recovery.
Results: The analysis population was 40,435 patients aged 35 years, from Asia-Pacific, Eur-
ope, the Americas and Middle East/Africa. Most were male (63.1%), mean age 60.4 years
and current or ex-smokers (60.6%) with history of 2 exacerbations in the previous year.
Patients who underwent spirometry (nZ 6408, 19.7%) had moderate airflow obstruction (mean
FEV1 1.7 L). Both clinicians and patients reported that moxifloxacin provided clinical improve-
ment in a mean of 3 days and recovery in 6 days. Clinical factors significantly associated with
late recovery were: age 65 years, duration of chronic bronchitis >10 years, cardiac comor-
bidity, >3 exacerbations in the previous 12 months, current exacerbation type (Anthonisen
I/II) and hospitalization in the last 12 months.f Texas Health Science Center at San Antonio, Pulmonary/Critical Care, 111E, 7400 Merton Minter
Tel.: þ1 210 617 5256; fax: þ1 210 949 3006.
edu (A. Anzueto).
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Identifying risk factors for late recovery in AECB 1259Conclusions: In a large cohort of patients, all treated with the same antibiotic for an
exacerbation of chronic bronchitis or COPD, the main factors associated with late recovery
(8 days) were: older age, history of frequent exacerbations, current exacerbation type of
Anthonisen I/II, history of prior hospitalizations and cardiac comorbid conditions.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Chronic bronchitis and chronic obstructive pulmonary disease
(COPD) together comprise a large and increasing health and
economic burden,1 with acute exacerbations of these
diseases contributing significantly to the burden and
progression of disease.2e4 COPD is projected to become the
third most frequent cause of death worldwide by the year
2030,1 and ranks fifth in terms of the global burden of
disease.4 Despite the major impact of these conditions on
patients and healthcare systems, relatively little is known of
the epidemiology of exacerbations of COPD (AECOPD) or
chronicbronchitis (AECB); large-scaleepidemiological studies
of patients experiencing acute exacerbations are rare.
Important treatment goals for AECB/AECOPD are to
reduce the duration of an exacerbation and to increase the
time to the next exacerbation. Factors affecting long- and
short-term clinical outcomes in patients with AECB/
AECOPD have been examined previously by Wilson et al.5
Clinical cure was positively influenced by antibiotic treat-
ment choice; higher cure rates were seen for moxifloxacin
than comparator (amoxicillin, clarithromycin, cefuroxime)-
treated patients, while cardiopulmonary disease, forced
expiratory volume in 1 s (FEV1) <50% predicted and 4
exacerbations in the previous year were indicative of
a poorer treatment outcome.
The Greatest International ANtibiotic Trial (GIANT) trial
provides data from a large observational cohort of patients
who were all treated with the same antibiotic (moxi-
floxacin). As antibiotic treatment itself influences treat-
ment outcome, using a single antibiotic should eliminate
potential bias due to the type of antibiotic used.
Results from more than 9200 patients in the European
regions of the GIANT study6 and 11,377 patients from China7
have been reported previously. This manuscript is the
report of the full data set from the GIANT study (gathered
across 46 countries over 4 years).
The GIANT study provided a large database that has been
used to assess the risk factors for delayed recovery from an
exacerbation in a real-life situation outside the regimented
environment of a clinical trial. To standardize one potential
variable, all patients received the same antibiotic treat-
ment. Knowledge of factors that predispose patients to
early or late recovery (8 days) may help to guide clinicians
in their treatment choices, their advice to patients, and
will have an impact on the future design of clinical studies.
Methods
Study design
GIANT was a prospective, multicenter, observational, non-
interventional study that collected data on theepidemiology and outcomes of patients with AECB between
February 2004 and November 2007. The study was con-
ducted in Asia-Pacific, Europe, the Americas, and the Middle
East/Africa (see Supplementary Material for a full list of
participating countries). A standard protocol was used and
all doctor and patient documentation was translated into
appropriate languages. Patients were treated with moxi-
floxacin in accordance with local labeling, guidelines and
ethical approval rules in participating countries.
Patients
Patients were enrolled in the study if they were suffering
from an AECB/AECOPD and their clinician determined that
they should receive treatment with an antibiotic. All
patients were treated with open label, oral moxifloxacin,
400 mg once a day for 5e10 days. All clinical decisions
about selection and implementation of individual medical
treatment and diagnostic measurements were made by the
participating clinicians. The populations analyzed in the
GIANT study are shown in Fig. 1. For the overall analysis of
patient characteristics and the subanalyses by type of
exacerbation and time to recovery, only patients aged 35
years were included. The lower age limit of 35 years was
chosen to exclude those patients most likely to have had
acute bronchitis and/or asthma rather than AECB/AECOPD.
Exacerbation definition and severity
The occurrence of an exacerbation was diagnosed based on
the patient experiencing an acute increase in one or more
of the respiratory symptoms of dyspnea, sputum volume
and sputum purulence. These are the three clinical symp-
toms described by Anthonisen et al.8 Patients were classi-
fied according to their symptoms as: type I exacerbations
were those with all three symptoms, type II exacerbations
were those with any two of the three symptoms and type III
exacerbations were those in which any one of these
symptoms was present. Recovery was assessed by the
clinician and was defined as a cure, resulting in the patient
being free of the symptoms of an acute exacerbation.
Study procedures
For each patient enrolled, baseline data on patient demo-
graphic and clinical characteristics were recorded. These
included age, gender, body mass index (BMI), smoking
status, employment status, duration of chronic bronchitis,
number of exacerbations in the previous year, clinician
visits and hospitalizations in the previous year, FEV1,
concomitant diseases (including COPD), symptoms of the
current exacerbation according to Anthonisen criteria,8
severity of the current exacerbation (as assessed by the
All patients enrolled 
N=47865
Safety population
All patients who took at least one dose of moxifloxacin
N=46,893
Population for analysis by type of exacerbation
Patients ≥35 years but excluding those with insufficient data 
on type of exacerbation
N=37,053
Patients valid for efficacy analysis
All patients who took at least one dose of moxifloxacin and had 
sufficient follow-up information on the course of their exacerbations 
well as the final assessment of effectiveness by the physician
N=46,893
Population for analysis of patient characteristics
overall and by region
All patients ≥35 years
N=40,435
Population for analysis of factors related to early or 
late recovery
Patients ≥35 years but excluding those with insufficient data 
on recovery time or with a recovery time of 5–7 days 
N=15,751
Anthonisen I + II
N=24,139
Anthonisen III
N=12,914
Early recovery ( 4 days)
N=9733
Late recovery (≥≥ 8 days)
N=6018
Excluded (N=972)
Initial visit date before start of study, n=690
Insufficient documentation , n=177
Lost to short-term follow-up (no proof of 
moxifloxacin intake), n=53
No symptoms at initial visit (presence of an acute 
exacerbation required for inclusion), n=49
No moxifloxacin given, n=3
Figure 1 Disposition of patients in the various analysis populations of the GIANT study.
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exacerbation (effects on daily activities and on sleep
patterns as assessed by the patient), previous treatment for
exacerbations and concomitant medication.
The study period covered the course of moxifloxacin
treatment. There was no formal schedule of visits. Patients
were seen as often as necessary in line with routine prac-
tice in that region (generally one or two follow-up visits).
The clinician made an assessment of time to improvement
in symptoms and time to recovery. At each follow-up visit,
the patient’s symptoms, changes in concomitant medica-
tion and any adverse events were recorded using standard
adverse event report forms attached to the case report
form. At the final follow-up visit, an overall assessment of
treatment was made.
Study analyses
Descriptive analyses of the data were performed using
summary statistics for categorical and quantitative data.
Patient demographic and clinical characteristics were
analyzed according to region (Asia-Pacific, Europe, the
Americas and Middle East/Africa), exacerbation symptom
criteria (Anthonisen I plus II vs Anthonisen III) and time to
recovery in days. Patients were categorized into tertiles
based on recovery time: 4 days (early-recovery group),
5e7 days, or 8 days (late-recovery group), according to
previously published results on time to recovery.9,10 This
distribution resulted in three subgroups containing similar
numbers of patients. Patients who recovered most quickly(early-recovery group) were statistically compared with
those who had the most prolonged recovery (late-recovery
group) to maximize the likelihood of observing significant
differences, thus providing clear characterization of the
patients at risk of late recovery, which is the main objec-
tive of the analysis.
Simultaneous comparisons were carried out using multi-
factorial test statistics (analysis of variance [ANOVA],
Pearson’s c2 test). Differences between subgroups of
patients were analyzed using the Wilcoxon rank sum test.
Amultivariate analysis was also carried out using a backward
selection model, in which clinical and demographic factors
were entered initially and then terms that were not signifi-
cant (P  0.05) were excluded. The factors included were
gender (male vs female), geographic area (each region vs
others), age (65 vs <65 years), BMI (<20 vs 20 kg/m2),
duration of chronic bronchitis (<10 years vs 10 years),
current smoking history (yes vs no), cardiac comorbidity (yes
vs no), FEV1 assessed at baseline (yes vs no), exacerbations
in the previous 12 months (3 vs <3), hospitalization in
the previous 12 months (yes vs no) and severity of exacer-
bation based on Anthonisen criteria (I þ II vs III).Results
Patient populations
The safety population consisted of 46,893 patients who
received at least one dose of moxifloxacin (Fig. 1). The
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comprised 40,435 patients aged 35 years. These patients
were included in the overall analysis of baseline demo-
graphics and clinical characteristics, and the analysis by
region (Asia-Pacific: n Z 25,074, Europe: n Z 10,164, the
Americas: nZ 2487, and Middle East/Africa: nZ 2710). Of
the 40,435 patients 52.0% had a concomitant diagnosis of
COPD (Table 1).
The patient populations for the exacerbation type and
time-to-recovery analyses were drawn from the primary
population aged 35 years old (Fig. 1). Of 37,053 patients
valid for analysis of exacerbation type, 24,139 had
Anthonisen type I or II and 12,914 had Anthonisen type III.
There were 15,751 patients valid for the analysis of
recovery time: 9733 were in the early-recovery group (4
days) and 6018 in the late-recovery group (8 days). Of
these, 11,486 patients had a full data set available for
statistical analysis, 6649 in the early-recovery group and
4837 in the late-recovery group.
Baseline demographics and clinical characteristics
The baseline demographics and clinical characteristics of
the population used for analysis are shown in Table 1. Most
patients were male (63.1%), mean age 60.4 years, current
or ex-smokers (60.6%) with a history of at least two exac-
erbations in the previous year. FEV1 assessments were
available for 6408 (19.7%) patients in the population and
demonstrated moderate airflow obstruction with a mean
FEV1 of 1.7 L. Nearly two-thirds of the patients were
suffering from an Anthonisen type I or II exacerbation.
There were variations in patient profiles across the
different regions, particularly in terms of smoking status,
duration of chronic bronchitis, disease severity and the
presence of comorbid cardiac disease, diabetes and other
lung disease (Table 1).
Systemic corticosteroids were given alone or in combi-
nation with inhaled corticosteroids in 9% of the study
cohort. Patients with more severe symptoms were more
likely to receive corticosteroids. There were no differences
in patients’ outcomes as compared to patients that did not
receive corticosteroids.
Patient demographic and clinical characteristics
according to type of exacerbation
Demographic and clinical characteristics were assessed by
the severity of the exacerbation (Anthonisen criteria).
Table 2 shows the characteristics of these patients.
Compared with patients in the Anthonisen Type III group,
patients in the Anthonisen I plus II group were more likely to
be male, aged >60 years, to be a current or ex-smoker and
to have had chronic bronchitis for more than 10 years. In
the last 12 months they were likely to have had more
exacerbations, more physician visits and more hospitaliza-
tions than those with a type III Anthonisen exacerbation.
For the current exacerbation, they were more likely to
have disturbance to daily activities and to have disturbed
sleep. Patients in the Anthonisen I plus II group were also
most likely to have associated comorbid conditions, such as
an underlying lung disease.Clinician- and patient-reported outcomes of
treatment with moxifloxacin
According to assessment by the treating clinician, the
mean time to clinical improvement after initiation of
treatment with moxifloxacin was 3.3 days. Time to
improvement was shortest in patients with Anthonisen class
III. The clinician-assessed mean time to recovery was 5.8
days.
Patient demographic and clinical characteristics
according to recovery time
Demographic characteristics of patients with early (4
days) vs late (8 days) recovery are shown in Table 3. In
both Europe and the Americas a higher proportion of
patients had late recovery. Patients in the late-recovery
group had a more serious disease profile than those in the
early-recovery group. Those with late recovery were older
(mean age of 63.8 years, 48.4% aged over 65 years vs mean
age 58.4 years; 32.0% aged 65 years), more likely to have
suffered from chronic bronchitis for >10 years, with more
exacerbation episodes overall in the past 12 months and
a greater likelihood of having >3 exacerbations in 12
months. A higher percentage of patients in the late-
recovery group were assessed by spirometry than in the
early-recovery group. The current exacerbation was more
severe in the late than in the early-recovery group; 72.3% of
patients were classed as Anthonisen class I or II in the late-
recovery group vs 49.8% in the early-recovery group.
Cardiac comorbidities were documented almost twice as
often in the late- (36.2%) vs the early- (19.9%) recovery
group and there was a slightly higher rate of hospitalization
in the late-recovery group.
Results of the multivariate logistic regression analysis of
risk factors for late recovery are shown in Table 4. Clinical
and patient-related factors most strongly associated with
late recovery were age 65 years, duration of chronic
bronchitis >10 years, presence of cardiac comorbidity,
having >3 exacerbations in the previous 12 months, having
a current exacerbation as Anthonisen type I or II, and being
hospitalized in the last 12 months. Patients assessed by
spirometry were also more likely to be in the late-recovery
group.
Safety and tolerability
Adverse events were recorded for 1.8% of patients in the
safety population (847/46,893) during the treatment
period. They led to permanent discontinuation of therapy
in 0.3% of patients (155/46,893). Adverse drug reactions
(ADRs) occurred in 1.2% (557/46,893) of patients. The
predominant ADRs were gastrointestinal (n Z 353/46,893
patients; 0.8%): nausea (139 [0.3%] patients), diarrhea (93
[0.2%] patients) and vomiting (57 [0.1%] patients). Of the
46,893 patients, 0.2% (96) had at least one serious adverse
event. Serious adverse events with fatal outcome were
reported in 46 (0.1%) patients; only one death was associ-
ated with therapy. This patient with a history of COPD
developed concomitant pulmonary embolism in the context
of sepsis and renal insufficiency.
Table 1 Patient demographic and clinical characteristics of the patient population aged 35 years.
Total
(N Z 40,435)
Asia-Pacific
(N Z 25,074)
Europe
(N Z 10,164)
Americas
(N Z 2487)
Middle East/
Africa
(N Z 2710)
P-valuea
Investigator specialty, %b <0.0001c
Family clinician 20.7 11.3 51.2 1.5 10.8
Chest clinician 65.1 79.0 38.4 60.8 41.1
Male sex, % 63.1 66.6 55.9 50.5 69.7 <0.0001c
Age (years), mean (SD) 60.4 (13.1) 60.0 (13.2) 62.2 (12.6) 64.6 (12.7) 53.3 (11.3) <0.0001d
BMI (kg/m2), mean (SD) 24.7 (4.6) 23.3 (3.9) 26.8 (4.5) 26.4 (5.0) 27.7 (5.1) <0.0001d
Smoking status, % <0.0001c
Current smokers 29.7 28.6 30.2 25.0 42.1
Ex-smokers 30.9 30.8 30.8 42.7 21.5
Never smoked 38.0 40.0 37.2 29.9 30.7
In employment, % 40.3 43.0 33.8 31.2 47.7 <0.0001c
Chronic bronchitis for >10 years, % 19.3 15.6 29.9 21.0 12.7 <0.0001c
FEV1 (L), mean (SD) 1.7 (0.8) 1.6 (0.8) 1.8 (0.8) 1.5 (0.7) 1.8 (0.9) <0.0001
d
Patients assessed by spirometry, n (%) 6408 (19.7)e 1803 (10.5)e (3533 34.8) 704 (28.3) 368 (13.6)
Events in the past 12 months,
mean (SD)
Number of exacerbations 2.4 (2.2) 2.5 (2.3) 2.2 (1.9) 2.4 (2.0) 3.0 (2.6) <0.0001c
Clinician visits 3.2 (3.1) 2.7 (2.6) 4.5 (4.1) 3.0 (2.6) 3.1 (2.7) <0.0001c
Hospitalizations 0.6 (1.1) 0.8 (1.1) 0.3 (0.8) 0.5 (1.1) 0.4 (1.1) <0.0001c
Disruptions during previous
exacerbations, mean (SD)
Days daily activities affected 5.3 (5.8) 4.4 (5.2) 7.7 (6.6) 5.9 (7.0) 4.7 (4.9) <0.0001c
Nights with sleep disturbance 3.5 (4.5) 2.9 (3.8) 4.8 (5.5) 3.9 (5.5) 3.5 (4.2) <0.0001c
Characterization of current
exacerbation
according to Anthonisen criteria, %
<0.0001b
Anthonisen type I 26.3 19.5 38.9 32.6 36.4
Anthonisen type II 33.4 33.1 34.5 31.7 33.1
Anthonisen type III 31.9 36.5 23.0 30.3 25.1
Severity of current exacerbation
according to investigator’s
judgment, %
<0.0001b
Mild 16.4 20.4 8.1 16.3 10.3
Moderate 63.8 65.0 62.5 62.4 58.3
Severe 19.5 14.2 29.1 20.7 30.6
Comorbid conditions, %f
None 18.6 20.7 14.0 13.3 21.1
Cardiac disease(s) 25.1 23.6 32.3 23.8 13.7
Diabetes 13.6 12.3 14.8 14.2 19.7
Lung disease(s) 71.1 67.6 78.3 77.8 70.1
COPD 52.0 46.4 63.1 66.4 49.9
Aggregate percentages vary and are less than 100 due to missing values.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; SD, standard deviation.
Anthonisen type I: increased dyspnea, sputum volume, and sputum purulence present; Anthonisen type II: two of increased dyspnea,
sputum volume, or sputum purulence present; Anthonisen type III: one of increased dyspnea, sputum volume, or sputum purulence
present.
a Europe was used as the reference group; each region was tested against Europe, not against the other regions.
b Chest clinicians include pulmonologists and internal medicine specialists; the numbers of investigators in other clinical specialties are
not shown.
c c2 test.
d ANOVA.
e FEV1 was not documented in the Philippines so the percentages in this table for the total population and for Asia-Pacific were
calculated without 7862 patients from Philippines; this makes the percentage of patients in Asia-Pacific with an FEV1 assessment
artificially low.
f Patients may have more than one comorbid condition.
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Table 2 Patient characteristics according to severity of the exacerbation (Anthonisen type I plus type II vs Anthonisen type III)
in the population of 37,053 patients aged 35 years who were valid for inclusion in the severity analysis.
Characteristic Anthonisen I plus II (N Z 24,139) Anthonisen III (N Z 12,914) P-value
Male sex, n (%) 15,605 (64.6) 7966 (61.7) <0.001a
Age (years), mean (SD) 61.7 (12.7) 59.0 (13.3) <0.001b
BMI (kg/m2), mean (SD) 24.9 (4.6) 24.4 (4.4) <0.001b
Smoking status, n (%) <0.001a
Current and ex-smokers 15,733 (65.2) 7190 (55.7)
Never smoked 8096 (33.5) 5538 (42.9)
In employment, n (%) 8822 (36.5) 5802 (44.9) <0.001a
Chronic bronchitis for >10 years, n (%) 5815 (24.1) 1759 (13.6) <0.001a
FEV1 (L) in patients assessed, mean (SD)
c 1.7 (0.8) (n Z 4873) 1.8 (0.8) (n Z 1374) <0.001b
Events in the past 12 months, mean (SD)
Exacerbations 2.7 (2.3) 2.2 (2.1) <0.001b
Clinician visits 3.5 (3.3) 2.7 (2.7) <0.001b
Hospitalizations 0.7 (1.1) 0.5 (1.0) <0.001b
Previous exacerbation, mean (SD)
Days with daily activities affected 6.2 (6.1) 4.2 (5.3) <0.001b
Nights with sleep disturbances 4.1 (4.8) 2.7 (3.9) <0.001b
Comorbid conditions, n (%)d
Lung disease(s) 18,844 (78.1) 8166 (63.2) <0.001a
Other 3319 (13.7) 2966 (23.0) <0.001a
Aggregate percentages vary and are less than 100 due to missing values.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; SD, standard deviation.
Anthonisen type I: increased dyspnea, sputum volume, and sputum purulence present; Anthonisen type II: two of increased dyspnea,
sputum volume, or sputum purulence present; Anthonisen type III: one of increased dyspnea, sputum volume, or sputum purulence
present and includes patients with one cardinal Anthonisen symptom and those with one cardinal symptom plus one or more minor
symptoms.
a c2 test.
b Wilcoxon rank sum test.
c FEV1 was not documented in the Philippines.
d Patients may have more than one comorbid condition.
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The GIANT study is the largest global investigation con-
ducted to date into the course and impact of episodes of
AECB/AECOPD in outpatients across Asia-Pacific, Europe,
the Americas, and the Middle East/Africa. The demo-
graphic and clinical data collected from the large database
of 46,893 patients allowed the development of demo-
graphic and clinical profiles of a ‘typical’ patient with
AECB/AECOPD as well as profiles of specific patient
subgroups, such as those with different severities of
exacerbation (Anthonisen I or II vs Anthonisen III) or
demonstrating early (4 days) or late (8 days) recovery.
The overall finding of the GIANT study is that in patients
who are all treated with the same antibiotic, baseline
patient demographic and clinical characteristics have
a major impact on the subsequent outcomes of treatment
for AECB/AECOPD.
A number of studies have described that patient-
related factors are important determinants of treatment
outcome.11e17 A computer-based general practice study
by Ball et al. found that a history of cardiopulmonary
disease and >4 exacerbations in the past 12 months were
risk factors for re-presenting with a further chest infec-
tion.11 In a retrospective chart analysis of patientstreated with a range of first-line antimicrobials, risk
factors associated with treatment failure were: FEV1
<35%, use of home oxygen, >3 exacerbations in the
previous year, a history of previous pneumonia or sinusitis
and use of maintenance corticosteroids. However, age,
comorbidity and the choice of antibiotic were not found
to be risk factors.12 Data from Spain indicated that FEV1
impairment, chronic mucus hypersecretion and increasing
age were associated with the risk of frequent exacerba-
tions.13 Another Spanish study, using data from general
practice,14 identified ischemic heart disease, the degree
of dyspnea and the number of visits to the general prac-
titioner in the previous year as strongly and indepen-
dently associated with treatment relapse. However, the
severity of exacerbation was not found to be associated
with the relapse rate. Thus, these studies have shown
that one or more of the following variables are risk factors
for poor short-term outcomes: age, severe airway
disease, comorbid cardiopulmonary disease, prolonged
chronic bronchitis or a high frequency of exacerbations.
However, these studies all included much smaller
numbers of patients than GIANT, included patients
treated with a range of antimicrobials, assessed only
a limited number of patient-related factors or were
specific to one region or country.
Table 3 Characteristics of patients in the groups with early recovery from an exacerbation (4 days) or late recovery from an
exacerbation (8 days) in 15,751 patients aged 35 years who were valid for the analysis of recovery time.
Characteristics Early recovery
(4 days)
(N Z 9733)a
Late recovery
(8 days)
(N Z 6018)a
P-value
Recovery time (days), mean (SD) 3.1 (0.9) 10.2 (2.5) <0.0001c
Investigators specialty, % <0.0001d
Family physician 23.3 24.8
Chest physician 62.2 62.3
Other 7.3 6.0
Missing 7.3 7.0
Gender, % 0.6659d
Male 62.4 62.9
Female 36.2 36.0
Missing 1.3 1.1
Age, mean (SD) 58.4 (13.2) 63.8 (12.5) <0.0001d
65 years, % 32.0 48.4 <0.0001d
Geographic area, % <0.0001d
Asia-Pacific 67.4 45.4
Europe 19.0 41.4
The Americas 5.4 7.3
Middle East/Africa 8.2 5.8
BMI (kg/m2), mean (SD) 24.7 (4.7) 25.2 (4.8) <0.0001c
Chronic bronchitis, % <0.0001d
10 years 85.9 65.9
>10 years 11.3 31.7
Missing 2.8 2.4
Smoking status, % <0.0001d
Current 31.1 28.2
Non-smoker or ex-smoker 67.5 70.5
Missing 1.4 1.3
Presence of cardiac comorbidity, % 19.9 36.2 <0.0001d
FEV1 (L), mean (SD)
b 1.8 (0.9) 1.7 (0.8) <0.0001c
Patients assessed, % 16.8 26.5
Exacerbations in last 12 months, mean (SD) 2.3 (2.2) 2.8 (2.3) <0.0001c
3, % 64.2 62.4 <0.0001d
>3, % 18.3 25.7
Missing, % 17.5 11.9
Hospitalizations in last 12 months, mean (SD) 0.6 (1.0) 0.7 (1.1) <0.0001c
Yes, % 29.3 38.1 <0.0001d
Current exacerbation symptoms, % <0.0001d
Anthonisen type I and II 49.8 72.3
Anthonisen type III 37.9 23.3
Missing 12.4 4.4
BMI, body mass index; FEV1, forced expiratory volume in 1 s; SD, standard deviation.
a Full data for all observations were available for 11,486 patients, 4265 patients were excluded from the various analyses due to
missing values; missing values are displayed in the table where appropriate.
b FEV1 was not documented in the Philippines so data from patients in the Philippines are not included in percentage calculations.
c Wilcoxon rank sum test.
d c2 test.
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interventional observational study to investigate a wide
range of potential risk factors for late recovery from
a treated exacerbation. A logistic regression analysis showed
that in this non-interventional study population there were
sevenkey risk factors for late recovery fromanexacerbation:
age 65 years, duration of chronic bronchitis >10 years,
presence of a cardiac comorbidity, multiple exacerbations
(>3) in the previous 12 months, current exacerbationclassified as Anthonisen I or II, hospitalization in the last 12
months and spirometry assessment. Smoking history had no
effect on the time to recovery e a finding supported by the
MOSAIC study5 inwhich current smoking history had no effect
on short-term clinical outcomes. Clear definition of the
patient profile associated with late recovery may allow
clinicians to identify patients at highest risk of poor outcome,
to choose the most appropriate antimicrobial treatment and
to plan their patient management accordingly.
Table 4 Factors associated with late recovery (8 days) from an exacerbation in 11,486 patients aged 35 years (early
recovery, n Z 6649; late recovery, n Z 4837) with a full data set available for all factors in the analysis.
Factor Odds ratio point
estimate
95% CI P-valuez
Region
Europe vs rest of world 2.589 2.343e2.861 <0.0001
Americas vs rest of world 1.756 1.495e2.062 <0.0001
Age
65 years vs 35e<65 years 1.233 1.130e1.345 <0.0001
Duration of chronic bronchitis
>10 years vs 10 years 2.262 2.041e2.506 <0.0001
Cardiac comorbidity
Yes vs no 1.559 1.421e1.711 <0.0001
Assessment of FEV1
Yes vs no 1.368 1.223e1.530 <0.0001
Number of exacerbations in last 12 months
>3 vs 3 1.147 1.044e1.260 0.0034
Anthonisen score
Anthonisen type I plus II vs Anthonisen type III 1.799 1.646e1.965 <0.0001
Hospitalization in last 12 months
Yes vs no 1.456 1.329e1.594 <0.0001
FEV1, forced expiratory volume in 1 s.
zc2 test.
Identifying risk factors for late recovery in AECB 1265The GIANT study has also highlighted that additional
clinician education may be required on the use of spirom-
etry. Despite guidelines recommending the use of spi-
rometry18e20 for the diagnosis or follow-up of COPD, in
patients with AECB/AECOPD spirometry is not performed
routinely in primary care21e24 even in regions with ready
access to equipment. The data presented here show that
FEV1 was measured in only about 20% of patients. The
spirometric data indicate that many of the patients in the
GIANT study had moderate airway obstruction, and having
used spirometry was significantly associated with late
recovery. This may be because many clinicians tended to
order the assessment only for more severely ill patients or
those with complications. The GIANT study also demon-
strates that across the world, clinicians are initiating anti-
biotic treatment in patients with Anthonisen III
exacerbations. However, for an exacerbation to be
considered of probable bacterial origin it must be associ-
ated with two or more Anthonisen criteria or even better,
with a change in sputum color25; current guidelines26,27
state that an exacerbation which is unlikely to be of
bacterial origin (i.e. Anthonisen III) should not be treated
with antibiotics.
Finally, in the GIANT study, where diagnosis and
management of an exacerbation reflected ‘real-life’
routine clinical practice, treatment with moxifloxacin was
effective and well tolerated both according to the clinician
and the patient. Patients felt better and were able to
resume their daily lives and clinicians reported clinical
improvement and recovery rates within 3e7 days. This is in
line with clinical response rates and adverse-event profiles
reported for moxifloxacin in clinical trials11,28,29 and
supports current recommendations that moxifloxacin is
suitable as (i) a first-line treatment option for patientspresenting with multiple risk factors for poor outcome,
(such as severe impairment of lung function, comorbid
disease(s), or frequent exacerbations),5 or (ii) as a second-
line treatment option for patients who experience initial
treatment failure.29
Limitations of the study
As the GIANT study was a non-randomized study, no control
group comparisons could be made between moxifloxacin
and placebo or another active treatment. However, as the
intention of the study was to gather baseline and on-
treatment data, such a comparison with another treatment
was never intended. Also, its non-interventional design
resulted in a less rigid follow up than seen in randomized
controlled trials. The GIANT study provides data on over
40,000 patients, and gives a useful global picture when
viewed within the constraints of an observational study.
Another difference between an observational study and
a randomized, controlled trial is that the threshold for
reporting adverse events either from the patient to the
clinician or from the clinician can vary because it is not
possible to closely monitor safety in such a large pop-
ulation. However, the study did not reveal any unexpected
serious ADRs, so the study supports the established safety
profile of moxifloxacin.29
Other possible limitations include the fact that the
GIANT protocol relied on patient recall rather than clinical
records to obtain the exacerbation history and that some
assessments were based on the investigators’ judgment
alone (e.g. time to improvement, time to cure and
Anthonisen grade). However, recent studies have shown
that patient history of previous exacerbations accurately
reflects future events.30,31
1266 A. Anzueto et al.Finally, it is possible that the percentage of patients
with a recording of FEV1 could be an underestimate, as in
some instances it is possible that the investigator recording
the study data did not know, or did not remember whether
this had been done.
Conclusions
Marked differences were seen across regions in the char-
acteristics of patients presenting with AECB/AECOPD. Late
recovery from AECB/AECOPD in patients treated with an
appropriate antimicrobial is more likely to occur in older
patients, those with a longer duration of chronic bronchitis
or COPD, more severe disease, cardiac comorbidity, or
a history of >3 exacerbations per year. Clinical studies
should be designed to take these risk factors into
consideration.
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